Review Article
Volume 4 Issue 2 - 2020
Myasthenia Gravis: Trend of Therapeutic Agents in the Management of the Disease
Chika J Mbah*
Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Enugu State, Nigeria
*Corresponding Author: Chika J Mbah, Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Enugu State, Nigeria.
Received: December 22, 2019; Published: January 08, 2020


Myasthenia gravis (MG) is an autoimmune disease caused by autoantibodies against the nicotinic acetylcholine receptors on the postsynaptic membrane at the neuromuscular junction. It is characterized by weakness and fatigability of the voluntary muscles. The objective of the study was to provide the trend of therapeutic agents utilized in the treatment of myasthenia gravis. The methodology utilized published works in scientific journals, official books and other medical and pharmaceutical relevant books to gather relevant information. Academic institution library as well as the internet websites offered assistance in the information gathering. The results have shown that the trend of these therapeutic agents against myasthenia gravis is acetylcholinesterase inhibitors, corticosteroids, immunosuppressants and immunomodulators and new chemical entities awaiting approval. The study suggests that drug treatment of myasthenia gravis is highly successful and has in combination with other treatment procedures very significantly reduced the mortality of patients with myasthenia gravis to near zero.

Keywords: Myasthenia Gravis (MG); Autoimmune Disease; Neuromuscular Junction (NMJ)


  1. Drachman DB. “Myasthenia gravis”. New England Journal Medicine 330 (1994): 1797-1810.
  2. Hill M. “The neuromuscular junction disorders”. Journal Neurology Neurosurgery Psychiatry 74.2 (2003): 32-37.
  3. Jordan A and Freimer M . “Recent advances in understanding and managing myasthenia gravis”. F1000 Research 7 (2018): F1000.
  4. Engel AG and Arahata K. “The membrane attack complex of complement at the endplate in myasthenia gravis”. Annal New York Academy Science 505 (1987): 326-332.
  5. Thanvi BR and Lo TCN. “Update on myasthenia gravis”. Postgraduate Medical Journal 80 (2004): 690-700.
  6. Hehir MKand Silvestri NJ. “Generalized Myasthenia Gravis: Classification, Clinical Presentation, Natural History, and Epidemiology”. Neurology Clinical 36.2 (2018): 253-260.
  7. Mantegazza R., et al. “Current and emerging therapies for the treatment of myasthenia gravis”. Neuropsychiatric Disease Treatment 7 (2011): 151-160.
  8. Dau PC., et al. “Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis”. New England Journal Medicine 297 (1977): 1134-1135.
  9. Gajdos P., et al. “Plasma exchange for myasthenia gravis”. Cochrane Database System Review 4 (2002): CD002275.
  10. Pinching AJ and Peters DK. “Remission of myasthenia gravis following plasma-exchange”. Lancet 2 (1976): 1373-1376.
  11. Gronseth GS and Barohn RJ. “Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology”. Neurology 55.1 (2000): 7-15.
  12. Pritchard EAB. “The use of ‘‘Prostigmin’’in the treatment of myasthenia gravis”. Lancet (1935): 432-434.
  13. Merritt HH. “Corticotropin and cortisone in diseases of nervous system”. Yale Journal Biology Medicine 24 (1952): 466-473.
  14. Mertens HG., et al. “The treatment of severe myasthenia gravis with immunosuppressive agents”. European Neurology 2 (1969): 321-339.
  15. Zinman L., et al. “IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial”. Neurology 68.11 (2007): 837-841.
  16. Sieb JP and Köhler W. “Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial”. Clinical Neurology Neurosurgery 112.9 (2010): 781-784.
  17. Schneider-Gold C., et al. “Corticosteroids for myasthenia gravis”. Cochrane Database System Review 2 (2005): CD002828.
  18. Hart IK., et al. “Immunosuppressive agents for myasthenia gravis”. Cochrane Database System Review 4 (2007): CD005224.
  19. Mantegazza R., et al. “Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis”. Journal Neurology 235.8 (1988): 449-453.
  20. Tindall RS., et al. “A clinical therapeutic trial of cyclosporin in myasthenia gravis”. Annal New York Academy Science 681 (1993): 539-551.
  21. de Feo LG.,” Use of intravenous pulsed cyclophosphamide in severe, generalized my-asthenia gravis”. Muscle Nerve 26 (2002): 31-36.
  22. Muscle Study Group. “A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis”. Neurology 71.6 (2008): 394-399.
  23. Allison AC and Eugui EM. “Mycophenolate mofetil and its mechanisms of action”. Immunopharmacology 47 (2000): 85-118.
  24. Arsura EL. “Experience with intravenous immunoglobulin in myasthenia gravis”. Clinical Immunology Immunopathology 53 (1989): s170-179.
  25. Arsura EL., et al. “High dose intravenous immunoglobulin in the management of myasthenia gravis”. Archives Internal Medicine 146 (1986): 1365-1368.
  26. Wegner B and Ahmed I. “Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis”. Clinical Neurology Neurosurgery 105 (2002): 3-8.
  27. Howard JF., et al. “Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study”. Lancet Neurology 16.12 (2017) : 976-986.
  28. Lebrun C., et al. “Successful treatment of refractory generalized myasthenia gravis with rituximab”. European Journal Neurology 16.2 (2009): 246-250. 
  29. Stieglbauer K., et al.” Rituximab for myasthenia gravis: three case reports and review of the literature”. Journal Neurology Science 280.1-2 (2009): 120-122.
  30. Rowin J., et al. “Etanercept treatment in corticosteroid-dependent myasthenia gravis”. Neurology 63.12 (2004): 2390-2392.
  31. Tuzun E., et al. “Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment”. Journal Auto Immununology 24.3 (2005): 261-268.
  32. Christadoss P., et al. “Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis”. Annal New York Academy Science 1132 (2008): 210-219.
  33. Sussman JD., et al. “Antisense treatment for myasthenia gravis: experience with monarsen”. Annal New York Academy Science 1132 (2008): 283-290.
  34. Kiessling P., et al. “The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study”. Science Translational Medicine 9.414 (2017): eaan1208.
  35. 2018 Emerging Science Abstracts. Neurology 90.24 (2018): e2182-e2194.
Citation: Chika J Mbah. “Myasthenia Gravis: Trend of Therapeutic Agents in the Management of the Disease”. EC Emergency Medicine and Critical Care 4.2 (2020): 01-06.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

June Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the June issue of respective journals and can be viewed in the current issue pages.

Submission Deadline for August Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the August issue of respective journals. Submissions are accepted on/before July 13, 2020.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to